- Recursion Pharma is hoping to revolutionize drug discovery with its Recursion OS technology; potential to improve drug discovery and processing capabilities.
- Recent deal with Roche brought in an upfront payment of $150 million, with potential to earn up to $300 million for each of the 40 programs to possibly be advanced.
- Deal with Bayer for Recursion OS brought in $30 million upfront payment plus potential to earn up to $100 million for each of the 12 programs to possibly be advanced.
- There will be 4 clinical candidates from the internal pipeline that will be advanced to treat rare diseases in phase 2 or phase 2/3 studies; these studies are expected to initiate in early 2022.
For further details see:
Recursion: Recursion OS Technology Has Potential To Revolutionize Biological Drug Discovery